We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Gene therapy start-up Homology Medicines raises $43.5mm in Series A capital
14 Nov 2017
Executive Summary
Homology Medicines Inc. (gene therapy for rare diseases) raised $43.5mm in its Series A financing round. The preferred stock financing was led by 5AM Ventures and ARCH Venture Partners with participation from Temasek, Deerfield Management, and ARCH Overage Fund. The company also appointed its leadership and advisory board.
Deal Industry
Pharmaceuticals
Biotechnology
Gene Therapy, Cell Therapy
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?